Platelets News and Research

RSS

ESC publishes position paper to raise the profile of vulnerable plaques

The European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology has published a position paper to raise the profile of vulnerable plaques and the need for greater use of therapies to promote plaque stabilisation.

15 Jun 2011

Ilex, Cerus partner to distribute INTERCEPT Blood System in Israel and South Africa

Cerus Corporation today announced today that it has entered into agreements with Ilex Biotech Limited to distribute Cerus' INTERCEPT Blood System for platelets and plasma in South Africa and Israel.

9 Jun 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

AspirinWorks Test now available in greater Boston and surrounding area

A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks Test is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine.

11 May 2011

Researchers find temperature-sensing protein in immune cells

Researchers at The Scripps Research Institute have found a temperature-sensing protein within immune cells that, when tripped, allows calcium to pour in and activate an immune response.

7 May 2011

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 1 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

27 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

BioParadox's VitaKine PCT can serve as promising therapy for heart attack patients

BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.

8 Apr 2011

Study: Antidepressants can thicken arteries and lead to heart disease

Antidepressant use has been linked to thicker arteries, possibly contributing to the risk of heart disease and stroke, in a study of twin veterans. The data is being presented Tuesday, April 5 at the American College of Cardiology meeting in New Orleans.

4 Apr 2011

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

23 Mar 2011

Major breakthrough in thrombosis

Scientists from the University of Reading have announced a major breakthrough in understanding how to control blood clotting which could lead to the development of new treatments and save the lives of thousands of people each year.

17 Mar 2011

Tiniest pollution particles can contribute to cardiovascular disease in diabetic people

Scientists are untangling how the tiniest pollution particles - which we take in with every breath we breathe - affect our health, making people more vulnerable to cardiovascular and respiratory problems.

10 Mar 2011

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

Study reveals expansion of NK cells after acute infection

The natural killer cells of our immune defense are activated for an extended period after the acute infection, which challenges the prevailing view that the elevation and activation of cells quickly pass.

3 Mar 2011

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT) today announced it has received a $2,075 million two-year grant from the U.S. Army to study the Company’s proprietary Oxycyte® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).

2 Mar 2011

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Oxygen Biotherapeutics, Inc. today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury.

2 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

Refrigerated whole blood may have shelf life beyond current standard of 24 to 48 hours

In a finding that may potentially improve survival from war injuries and disasters, laboratory researchers report that refrigerated whole blood may have a shelf life well beyond the current standard of 24 to 48 hours.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.